Navigation Links
Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
Date:9/25/2007

STOUGHTON, Mass., Sept. 25 /PRNewswire/ -- Cardiosolutions, Inc. (http://www.cardiosolutionsinc.com) has closed a $7 million Series A Convertible Preferred Stock financing led by BioVentures Investors, the company announced today. Cardiosolutions is developing a proprietary, minimally invasive system for repair of a regurgitant mitral valve interfering with normal heart function. The financing will fund pilot human trials of the technology, expected in 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070925/NETU085LOGO )

Mitral regurgitation is the most common type of heart valve insufficiency. It is a long-term disorder in which the valve that separates the left upper chamber of the heart (atrium) from the left lower chamber (ventricle) does not close properly. Debilitating chronic mitral regurgitation affects approximately 6% of women and 3% of men and currently requires open heart surgery for restoration of valve function.

Cardiosolution's Spacer - Tek Technology(TM) utilizes minimally invasive techniques similar to coronary stenting and mitral valvuloplasty. The Company's Percu - Pro System(TM) measures the pumping chambers of the heart and then delivers a proprietary Mitra - Spacer(TM) to the affected valve through a series of small catheters that are threaded into the blood vessels of the patient's inner thigh. This percuntaneous system is designed to greatly reduce the degree of mitral regurgitation in patients with either functional or degenerative valve disease and may allow patients to avoid open heart surgery, a difficult procedure with far greater risk, an extended period of recovery, and significantly greater cost.

"Completing this round of financing is a significant achievement for us and we are very pleased to have BioVentures Investors join our list of backers," stated Jon
'/>"/>

SOURCE Cardiosolutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. TomoTherapy raises $223 million in IPO
2. Fusion 2007: CA chief says IT complexity raises risk
3. Inline intellectual property raises legal issues
4. Biotech with Madison ties raises $21M in capital
5. ConjuGon raises $3.3 million to fund clinical trials
6. Nerites raises $1 million to improve medical tech
7. Brady Corp. raises $137 million in public offering
8. aOva Technologies raises $3 million
9. Bush praises Johnson Controls battery tech in Milwaukee visit
10. Anthropology professors blog raises public interest
11. Mithridion raises $1.6M through angel networks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...DIEGO, Dec. 4 Favrille, ...rds.com, Inc. ("MMR"), a health,information compa...ic Personal,Health Records (PHRs), announced toda...e closing of their definitive merger agreement hav...om/cgi-bin/prnh/20080404/LAF521LOGO ) , "We...
(Date:12/4/2008)...NTA and LACHEN, Switzerland, Dec. 4 /PRNewswire/ -...nounced that Dennis D. Curtin has been,selected t...d States. Curtin,had been Octapharma,s U.S. legal...nt of Life Therapeutics, Inc. , The largest...apharma,recently acquired Life Therapeutics, the ...
(Date:12/4/2008)...ANNE, Switzerland, December 4 AC I...velopment, announced today that the World,Economi...r 2009 for its,accomplishments as an innovation l...can have a deep impact on business and society. ,... reached significant clinical,milestones in the d...
(Date:12/4/2008)...HERSBURG, Md., Dec. 4 MedImmune to...nical trial in patients with chronic asthma to,de...anized monoclonal antibody,(MAb) that targets the...,suggest that inhibiting the IL-5R pathway may lea...th asthma, supporting continued study of this anti...
Breaking Biology Technology:Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 2Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 3Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 4Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 5Octapharma Names Dennis D. Curtin To Lead U.S. Plasma Operations 2Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development 2MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 2MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor 3
... Internet routers at homes and businesses are stil...adjunct Northwestern professor James Carlini in an...ting your wireless service with more ease than eve...used to describe dialing down a sequence of many p...) and trying to find a weakness or an opening into...
... who came to the Wisconsin Entrepreneurs Conferenc... variety of reasons: to gain information on starti... and establish connections with fellow entrepreneu...cheon on Tuesday, something else was provided to t...tives by the guest speakers: inspiration. During ...
...thing you know about nanotechnology is from that G... the super-model, and within the space of about 30...e a nerdy baby wearing eyeglasses. , ,Dont feel le...t nano over your neighbors backyard grill. The fie...have trouble keeping track. Thats a primary reason...
...nosha native discusses LOTR experiences, future pl... Entrepreneurs Conference chose to follow a trend...days the speakers were award winners. However, Tue...porated, was there to receive a Seize the Day Awa...cts supervisor Jim Rygiel , came to talk with thr...
Other Biology Technology:Wardrivers now exploiting your wireless service with ease 2Wardrivers now exploiting your wireless service with ease 3Wardrivers now exploiting your wireless service with ease 4Celebrating Wisconsins entrepreneurial spirit 2Celebrating Wisconsins entrepreneurial spirit 3Small wonders: Intersection of biotech and nanotech will produce big advances 2Small wonders: Intersection of biotech and nanotech will produce big advances 3Lord of the Rings visual effects creator talks about entrepreneurial experiences 2Lord of the Rings visual effects creator talks about entrepreneurial experiences 3Lord of the Rings visual effects creator talks about entrepreneurial experiences 4
(Date:12/3/2008)...rective gene into mouse blood cells, scientists at...ated sickle cell disease pathology. In their studi...owed essentially no difference from normal mice. A...ene therapy to humans presents significant technic...ll become an important treatment for the disease. ...
(Date:12/3/2008)...ling to take their medication for a range of life-...a new university research project. , The 21-mont...sity of Nottingham and The University of Leicester...ith asthma, diabetes, congenital heart disease and... them from taking medicines prescribed for them. ,...
(Date:12/3/2008)...e first tandem mission between ERS-2 and Envisat l...er again to help improve our understanding of the ...nvisat, the largest environmental satellite ever b...struments that provide high resolution images of t...AR images of the same site, slight alterations tha...
(Date:12/3/2008)..., the International Society for Stem Cell Research...ation of stem cell researchers, released new guide...effective stem cell therapies for patients. A Comm...the Clinical Translation of Stem Cells will be pub...l Stem Cell , the official affiliated journal of t...
Breaking Biology News(10 mins):Gene therapy corrects sickle cell disease in laboratory study 2Gene therapy corrects sickle cell disease in laboratory study 3A spoonful of sugar? 2A spoonful of sugar? 3ESA satellites flying in formation 2The International Society for Stem Cell Research releases new guidelines 2The International Society for Stem Cell Research releases new guidelines 3Omnicell to Release Second Quarter 2008 Earnings Results on July 21 23731 1Omnicell to Release Second Quarter 2008 Earnings Results on July 21 23731 2Common Mechanisms May Contribute to Autisms Mutations 23728 1Common Mechanisms May Contribute to Autisms Mutations 23728 2Video 3A Chatto Skincare Unprecedented Breakthrough 23723 1Video 3A Chatto Skincare Unprecedented Breakthrough 23723 2Video 3A Chatto Skincare Unprecedented Breakthrough 23723 3Good news about 244 gas 3F Fewer traffic deaths 23721 1
...ish are wizards of camouflage. Adept at blending i... have a diverse range of body patterns and can swi...rch from MBL Marine Resources scientists, to appea...arch, confirms that while these masters of disguis...ey do so while being completely colorblind. , Whil...
... first time, scientists have documented an organ-s...ed in the April 18 edition of the journal Immunity...Diego (UCSD) School of Medicine outline the unique...strategies against microbial invasion. , "This inn...as probably designed to minimize collateral damage...
... hasn,t even hit hard yet this year, but it seems ...imply put, there are a lot more infectious invader...he big headlines, but they still knock people down...ach winter. , Metapneumovirus. Rhinoviruses. Coro...rus (RSV). Pronouncing the names of the microbes c...
...: Have a look at the videos: 1 & 2 , Che...st technique providing a real-time, molecule-by-mo.... Their direct observation of fluorescently tagged...eal-time footage of the birth of individual new pr...ists, precision in probing genetic activity. , Usi...
Other Biology News:Cuttlefish masters of disguise despite colorblindness 2Researchers reveal lung's unique innate immune system 2Flu not the only germ threat this time of year 2Flu not the only germ threat this time of year 3Flu not the only germ threat this time of year 4Molecule by molecule, new assay shows real-time gene activity 2Molecule by molecule, new assay shows real-time gene activity 3
...lvement of integrins in vascular proliferation, ad.... The integrin family of cell adhesion receptors c...imers, composed of an a and b subunit that associa...ctional diversity of the integrin family are based...
...ep ion exchange media are rigid macroporous hydrop...flow rates at moderate pressures, while the macrop... hydrophilic matrix reduces nonspecific binding. M... anion exchanger with very high flow rates and res...
siTrio siRNA --- a cocktail of 3 siRNAs specifically targeted to your target gene of interestis our most popular product. The siTrio reagent guarantees you get more than 75% knockdown of your target
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112
Biology Products: